



BRAWN



0AF3C

CIN NO.: L74899DL1985PLC022468

To,
The Secretary,
Listing Department,
BSE Limited,
Floor 25, Phirozee Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

Date: 13-08-2019

Sub: Outcome of 3rd / 2019- 20 Board Meeting and Submission of Un-audited Financial Results for the quarter ended 30.06.2019

SCRIP CODE: 530207

Dear Sir/ Ma'am,

Pursuant to Regulations 30 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015, this is to inform you that the Board of Directors of the Company, at its meeting held today i.e. Tuesday, August 13, 2019 inter-alia considered and approved/noted the following:

1. Un-audited Standalone Financial Results of the Company for the quarter ended June 30, 2019 along with the Limited Review Report in this regard, a copy of the said Financial Results together with the Limited Review Report is enclosed herewith.
2. The 34th Annual General Meeting of the Shareholders of the company will be held on Saturday, the 21st Day of September, 2019 at 10:30 A.M at Dolly Farms & Resorts Private Limited, 439, Village Shaoorpur, P.O. Fathepuri, New Delhi.
3. Resignation of Mr. Brij Raj Gupta from the post of Managing Director of Brawn Biotech Limited.
4. Recommend to regularize Mr. Brij Raj Gupta (additional director) as director of the Company in ensuing Annual General Meeting of the Company.
5. Appointment of Mr. Mahesh Verma, as Manager (Key Managerial Personnel), for the term of 5 years.
6. Approved the Board's report of the Company for 34th Annual General Meeting of the Company.
7. Appointed Secretarial Auditor and Internal Auditor of the Company for the Financial Year 2019- 20.

BRAWN BIOTECH LTD.

(Formerly Known as Brawn Pharmaceuticals Ltd.)

Regd. Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462,
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Export Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

Corporate Office : Plot No. - 30, Sector - 33 , Near Hero Honda Factory, Gurugram (Haryana) 122001 , Tel.: 0124-4666152, 4222462
Email: solution@brawnbiotech.com

Works : 13, Industrial Area, N.I.T., Faridabad -121001 (Haryana) Tel.: +91 - 8010416849/48

... for better life.

The meeting of the Board of Directors commenced at 1:00 P.M. and concluded at 5:00 P.M.
Please acknowledge the receipt of the Letter and take the same on record.

You are requested to take above on record.

Thanking you,

For **BRAWN BIOTECH LIMITED**




Priyanka Sharma
Company Secretary & Compliance Officer
Encl: As above



BRAWN

CIN NO.: L74899DL1985PLC022468

BRAWN BIOTECH LIMITED CIN:L74899DL1985PLC022468 REGD. OFFICE: 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002					
STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2019				Rs. In Lacs	
Sr. No.	Particulars	Quarter Ended			Year Ended
		30-Jun-19 Un-audited	31-Mar-19 Audited	30-Jun-18 Un-audited	31-Mar-19 Audited
1	Revenue from operations				
	Revenue from operations	1,784.75	1,542.45	1,356.19	6,517.90
	Other Income	1.15	63.28	6.12	73.78
	Total Revenue	1,785.90	1,605.73	1,362.31	6,591.68
2	Expenses				
a	Cost of material consumed	-	-	-	-
b	Purchase of stock-in-trade	1,599.66	1,395.03	1,192.23	5,848.92
c	Change in inventories of finished goods, work in progress and stock in trade	(17.04)	(0.80)	7.11	0.90
d	Employee benefit expenses	52.86	81.45	57.71	302.49
e	Depreciation and amortisation expenses	0.79	0.79	0.80	3.20
f	Finance Cost	0.92	2.16	0.65	6.14
g	Other expenses	76.26	91.09	50.68	249.50
	Total Expenses	1,713.45	1,569.72	1,309.18	6,411.15
3	Profit from Operation before Other Income, exceptional and extra-ordinary items (1-2)	72.45	36.00	53.13	180.54
4	Other Income	-	-	-	-
5	Profit from ordinary activities before exceptional items (3-4)	72.45	36.00	53.13	180.54
6	Exceptional Items	-	-	-	-
7	Profit from ordinary activities before tax (5-6)	72.45	36.00	53.13	180.54
8	Tax Expenses	18.74	5.52	15.84	47.24
9	Profit (Loss) for the period from continuing operations (7-8)	53.71	30.49	37.29	133.29
10	Profit/(loss) from discontinuing operations	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-
12	Profit/(loss) from Discontinuing operations (after tax) (10-11)	-	-	-	-
13	Profit (Loss) for the period (9+12)	53.71	30.49	37.29	133.29
14	Other Comprehensive Income	(5.09)	0.07	3.82	5.53
	Total Comprehensive Income	48.62	30.56	41.11	138.82
15	Details of equity share capital	300.03	300.03	300.03	300.03
	Paid-up equity share capital				
	Face value of equity share capital				
16	Reserve excluding Revaluation Reserve				
17	Earnings per share				
i	Basic earnings per share	1.62	1.02	1.37	4.63
ii	Diluted earnings per share	1.62	1.02	1.37	4.63

NOTES:-

- Results for the quarter ended on 30th June, 2019 were reviewed by the Audit committee and then approved by the Board of Directors at their meeting held on 13th August, 2019.
- The Statutory Auditors carried out the limited review for quarter ended 30th June, 2019. The management has exercised necessary due diligence to ensure that the financial results provided a true and fair view of its affairs.
- The above results have been prepared in compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as amended by the Companies (Indian Accounting Standards) (Amendment) rules, 2016 prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
- The above Standalone Un-audited Financial Results for the quarter ended on 30.06.2019 are available on company's website www.brawnbiotech.com and BSE website www.bseindia.com.
- Previous year / period figures have been regrouped/ rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board
For Brawn Biotech Ltd.
Ajay K. Gupta
Managing Director
DIN NO. 00974969
Date: 13-08-2019
Place: Delhi
Authorised Signatory

BRAWN BIOTECH LTD.

(Formerly Known as Brawn Pharmaceuticals Ltd.)

...for better life

Regd. Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462,
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Export Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

Corporate Office : Plot No. - 30, Sector - 33 , Near Hero Honda Factory, Gurugram (Haryana) 122001 , Tel.: 0124-4666152, 4222462
Email: solution@brawnbiotech.com

Works : 13, Industrial Area, N.I.T., Faridabad -121001 (Haryana) Tel.: +91 - 8010416849/48



Independent Auditor's Report on Quarterly Standalone Financial Results of BRAWN BIOTECH LIMITED pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
**The Board of Directors of
Brawn Biotech Limited**

We have reviewed the accompanying statement of Unaudited Financial Results of **Brawn Biotech Limited** (the "Company") for the quarter ended 30th June 2019, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial results based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards i.e., Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Rajiv Udai & Associates
Chartered Accountants
Firm Registration No. 18764N**



**Rajeev Jain
(Partner)
(Membership No. 99767)
UDIN NO: 19099767AAAABW1467
Place: Delhi
Date: 13.08.2019**

